Equity Overview
Price & Market Data
Price: $0.885
Daily Change: +$0.005 / 0.56%
Range: $0.87 - $0.891
Market Cap: $3,456,358
Volume: 5,898
Performance Metrics
1 Week: -3.28%
1 Month: -10.51%
3 Months: -12.38%
6 Months: -25.32%
1 Year: -58.84%
YTD: -21.65%
Company Details
Employees: 17
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.